U s non oncology biopharmaceuticals market
U.S. Non-oncology Biopharmaceuticals Market, by Product Type (Biologics and Biosimilars), by Drug Class (Monoclonal Antibody, Enzyme Replacement Therapy, Erythropoietin, Interferon, Colony-stimulating Factor, Botulinum Toxin, Fusion Protein, Vaccines, Human Recombinant Insulin, Blood Factors, Human Growth Hormone, and Others), and by Disease Indication (Diabetes, Rheumatoid Arthritis, Psoriatic Arthritis, Multiple Sclerosis, Hemophilia, Anemia, Age-related Macular Degeneration, Hepatitis B, Cystic Fibrosis, Osteoporosis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Others (Cardiac Diseases and Others)) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028
- Apr 2019
- CMI2575
- 224 Pages
- Excel & Pdf
- Biotechnology
U.S. Non-oncology Biopharmaceuticals Market- Insights
Biologics can be defined as molecules derived from living cells such as microorganisms, plants or animal cells and used in the treatment, diagnosis or prevention of diseases. Most of the biologic molecules are very large, complex molecules or mixture of molecules.
Biopharmaceuticals are part of a wider category of therapeutic agents called biologics. Biopharmaceuticals are the substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs that are used in the treatment of various diseases rather than cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.
Increasing launches, approvals, and robust pipeline of novel biopharmaceuticals for non-oncology indications
Frequent approvals, launches, and robust pipeline of novel non-oncology biopharmaceuticals for various indications in the U.S. market is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth.
For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.
In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.
In July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).
Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026
Source: Coherent Market Insights Analysis (2018)
Increasing mergers and collaborations among key players for development of novel non-oncology biopharmaceuticals is expected to support the market growth
Key players in the market are involved in strategic mergers and collaborations for the development of new biopharmaceutical products and to market them in the U.S. Such strategic mergers and collaborations between key players is expected to support the development of novel products, which in turn is expected to fuel the U.S. non-oncology biopharmaceuticals market growth over the forecast period.
For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.
High price of branded biologic products is expected to be a major factor negatively affecting its adoption
According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.
Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.
Source: Coherent Market Insights Analysis (2018)
Market Opportunity
In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future.
Loss of patent in the U.S. market offers lucrative opportunity to other players for development of its biosimilars. Hence, key players in the market are focused on launch and development of biosimilars of biologic products in the market at affordable price.
For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc. As per the company, RENFLEXIS is introduced in the U.S. at a list price (wholesaler acquisition cost) of US$ 753.39, representing a 35% discount to the current list price of Remicade, which is its reference product.
Market Challenges
High R&D Investments: Developing an IV/injectable biopharmaceutical requires sophisticated infrastructure, skilled scientists, and significant resource investment. Development of a biopharmaceutical product requires extensive clinical research and multiple phases of trials, which is a lengthy and expensive process. These factors are significant barriers for the new players to enter the market.
Sales and Marketing: The U.S. non-oncology biopharmaceuticals market has established market players with strong sales and marketing team. Presence of such strong players in the country creates a big challenge for new players to enter the market and to sustain against such big players.
Physician Acceptance: Physician acceptance of substitutes for well-established products may be a challenge, particularly among indications for which numerous products are available and substitutes do not exhibit high/ better safety profile and/or lower cost.
Key players operating in the U.S. non-oncology biopharmaceuticals market include Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Approval/Launch
- Merger-Acquisition Scenario
- Regulatory Scenario
- Reimbursement Scenario
- Pest Analysis
- Market Challenges
- Top 10 Non-oncology Biologics Brand Share
- Major Biopharmaceuticals Administration Method
- Analysis Of Mode Of Administration
- Epidemiology
- Pest Analysis
- Porter’s Five Forces Analysis
- U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Botulinum Toxin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Colony-stimulating Factor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Erythropoietin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Fusion Protein
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Monoclonal Antibody
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Recombinant Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Age-related Macular Degeneration
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Anemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Crohn’s Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Cystic Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Hemophilia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Osteoporosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol - Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB Pharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Ltd
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LEO Pharma A/S
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alexion Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Elusys Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Swedish Orphan Biovitrum AB
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Samsung Bioepis NL B.V.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 35 market data tables and 38 figures on “U.S. Non-oncology Biopharmaceuticals Market – U.S. forecast to 2026”.
Detailed Segmentation:
- U.S. Non-oncology Biopharmaceuticals Market, By Product Type :
- Biologics
- Biosimilars
- U.S. Non-oncology Biopharmaceuticals Market, By Drug Class:
- Monoclonal Antibody
- Enzyme Replacement Therapy
- Erythropoietin
- Interferon
- Colony-stimulating Factor
- Botulinum Toxin
- Fusion Protein
- Vaccines
- Human Recombinant Insulin
- Blood Factors
- Human Growth Hormone
- Others
- U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication:
- Diabetes
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Multiple Sclerosis
- Hemophilia
- Anemia
- Age-related Macular Degeneration
- Hepatitis B
- Cystic Fibrosis
- Osteoporosis
- Crohn’s Disease
- Ulcerative Colitis
- Psoriasis
- Ankylosing Spondylitis
- Others (Cardiac diseases and others)